The Nuclear Medicine-PET Department is located on the -1 floor of the University Hospital of Bellvitge. It is managed jointly by the University Hospital of Bellvitge (Catalan Health Institute) and the Diagnostic Imagining Institute. It is answerable to the Clinical Diagnostic Imaging Management of the Southern Metropolitan Regional Management. It is a class-2 radioactive facility authorised by CSN/SCAR (IR-B/-IRA-2629). It includes its own Nuclear pharmacy unit authorised by the Generalitat de Catalunya Health Department as a functional unit that is also linked to the Pharmacy Department of the University Hospital of Bellvitge.
It is also a teaching unit that is accredited by the Ministry of Health, Social Services and Equality, with specialist Nuclear Medicine healthcare training places for physicians and Nuclear pharmacy places for pharmacists, chemists and biochemists, and it works with specialist professors in Radiodiagnosis, Radiophysics and Hospital Pharmacy. It has the specific support of the Physics and Radiation Protection Department of the Catalan Institute of Oncology-Hospitalet.
For the second year running (2017 and 2018), the Department’s 2 PET-CT teams have passed the annual accreditation requirements of the prestigious EARL programme by the European Association of Nuclear Medicine (EANM Research Ltd) as a Centre of Excellence in PET-CT. This accreditation is a prestigious international guarantee of the quality of its research activity, which encourages its participation in clinical trials. Most of these clinical trials involve new oncological treatments in which the PET-CT technique provides an objective response assessment. A growing field of new indications in research is cognitive impairment from suspected Alzheimer’s Disease.